Do Older Adults Need Routine Colonoscopies Or Low Thyroid Drugs?

Why It Matters

Continuing low‑value colonoscopies and thyroid medication inflates U.S. health‑care spending and exposes seniors to unnecessary complications, making evidence‑based deprescribing a critical quality‑of‑care priority.

Key Takeaways

• Colonoscopies after age 75 show <1% cancer incidence in veterans
• Medicare pays $650 per screening colonoscopy; hospital rates reach $1,100
• 64% of seniors on ≤50 µg levothyroxine stopped without harm
• Unnecessary levothyroxine prescriptions affect up to 23 million Americans

Pulse Analysis

The United States faces a paradox of abundant medical technology and rising overtreatment, especially among patients over 75. The JAMA veteran cohort, predominantly male, tracked colon cancer outcomes a decade after a pre‑75 colonoscopy and found post‑75 cancer rates of just 1.1% for those with prior polyps and 0.7% for those without. When juxtaposed with a 50% mortality rate from unrelated causes, the data reinforce the U.S. Preventive Services Task Force’s recommendation to individualize screening beyond age 75, favoring non‑invasive stool‑based tests when appropriate. This shift could spare seniors costly procedures—$650 under Medicare and $1,100 in hospital settings—while preserving quality of life.

Parallel concerns arise with levothyroxine, a low‑cost thyroid hormone replacement taken by roughly 23 million Americans. The Dutch JAMA study demonstrated that 64% of participants on doses of 50 µg or less could taper off the medication without clinical deterioration over 12 months. Given the drug’s side‑effect profile—including bone fractures, atrial fibrillation, and cognitive decline—deprescribing low‑dose regimens in patients over 60 presents a clear safety and economic win. At under $12 per month, the drug’s price is modest, yet the aggregate cost of unnecessary prescriptions and monitoring adds up across the health system.

These findings underscore a broader imperative: clinicians must embed routine benefit‑risk reassessments into geriatric care pathways. Shared decision‑making tools, electronic health‑record alerts, and payer incentives can help identify low‑value interventions before they become entrenched. By aligning practice with emerging evidence, the health‑care ecosystem can curb wasteful spending, reduce iatrogenic harm, and allocate resources toward interventions that truly improve outcomes for older adults.